EPS: As of FY2025 Q1, the actual value is USD -0.8, missing the estimate of USD -0.6011.<h3>Segment Revenue</h3>Biomea Fusion, Inc. has not generated any revenue from product sales since its inception.<h3>Operational Metrics</h3><ul><li>Net Loss: The company reported a net loss of - $29.3 million for the three months ended March 31, 2025, compared to a net loss of - $39.1 million for the same period in 2024.</li><li>Operating Expenses: Total operating expenses decreased from $41.1 million in Q1 2024 to $29.7 million in Q1 2025.</li><li>Research and Development Expenses: R&amp;D expenses decreased by $10.9 million, primarily due to reduced clinical activities and manufacturing costs.</li><li>General and Administrative Expenses: G&amp;A expenses decreased by $0.5 million, mainly due to reduced personnel-related expenses.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: The company used - $25.7 million in operating activities during the three months ended March 31, 2025, compared to - $32.0 million in the same period in 2024.</li><li>Net Cash Used in Investing Activities: No cash was used in investing activities during the three months ended March 31, 2025.</li><li>Net Cash Provided by Financing Activities: Financing activities provided $3.3 million during the three months ended March 31, 2025, primarily from the issuance of common stock under the 2022 ATM Program.</li></ul><h3>Unique Metrics</h3><ul><li>Stock-Based Compensation Expense: Total stock-based compensation expense was $3.2 million for the three months ended March 31, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to focus on developing icovamenib for metabolic disorders, specifically type 1 and type 2 diabetes, and aims to conclude oncology studies while exploring partnerships for its oncology assets.</li><li>Non-Core Business: Biomea Fusion, Inc. intends to explore partnerships to advance its oncology assets, including BMF-500, while concentrating internal resources on metabolic disorders.</li><li>Priority: The company acknowledges the need for additional capital to fund operations and plans to raise funds through public or private equity offerings, debt financings, collaborations, and licensing arrangements.</li></ul>

Biomea Fusion | 10-Q: FY2025 Q1 EPS Misses Estimate at USD -0.8